- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06170983
Skin Inflammation and PK of Azithromycin (AZI_IMQ_LPS)
Validation of Imiquimod- and LPS-induced Skin Inflammation Models and Their Application in the Investigation of Azithromycin Concentration in Inflamed, Infected, and Healthy Subcutaneous Tissue
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This single-center, prospective, open-label, adaptive, pharmacokinetic study will comprise three parts: Part 0a-c, Part A, and Part B.
Objectives: This study primarily aims to characterize and establish a new skin inflammation model using topically applied LPS. The secondary aim of this research is to deepen our understanding of the role of leukocytes as potential transport vehicles for macrolides and other antibiotics in humans.
Intervention: Part 0 will serve as a pilot experiment in healthy volunteers to validate the imiquimod and LPS challenge in a controlled design. The investigators will clinically assess the tolerability of increasing LPS doses and the already published design of the imiquimod challenge. In general, the investigators will perform the different designs of skin inflammation models using tape stripping and an occlusive 18-mm Finn chamber.
The inflammation will not only be clinically assessed but also objectively quantified using the imaging-based mobile phone application Scarletred®Vision. Considering these results, the investigators will again carry out the LPS and imiquimod challenge in healthy volunteers and additionally perform biopsies in Part 0c to collect specimens for flow cytometry. Thus, the investigators will be able to characterize the skin inflammation models at a cellular level. Using NGS, the investigators will also explore transcriptional changes within cell subset that are affected by the inflammation.
In Part 0c, the investigators will include 12 healthy volunteers and will perform in each subject three skin punch biopsies, including a negative control, IMQ-challenged skin and LPS-challenged skin. Using flow cytometry, the investigators will measure the infiltration of leukocytes subsets.
Part A will employ a skin inflammation challenge based on either LPS or the imiquimod according to the results of Part 0 (i.e., the one showing the greater leucocyte infiltration). Azithromycin will be given in parallel once daily for 3 consecutive days. After the last application (i.e. day 3), two microdialysis probes will be placed in the inflamed subcutaneous tissue and one will be placed in the unmanipulated healthy subcutaneous fat. Hereafter, PK sampling and microdialysis of two thighs will be performed for two consecutive days. The investigators will isolate leukocytes from blood samples on day 3 to determine the average concentration of azithromycin in them. Biopsies from the unmanipulated and the challenged skin will be obtained on day 4.
Part B will involve patients with skin infections including erysipelas and cellulitis at their lower extremities. In contrast to Part A, only one microdialysis probe will be placed into the infected subcutaneous tissue and one into healthy, unaffected tissue. After three doses of azithromycin, pharmacokinetic sampling, leukocyte isolation, and microdialysis of the healthy thigh and the respective area of infection will be performed.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
• Men and women aged ≥18 and <55 years
- BMI ≥18 and ≤30 kg/m2
- Normal (or clinically irrelevant abnormal) findings in medical history and physical examination
- Women with child-bearing potential: use of effective contraception
- Laboratory parameters within the given reference range (or abnormal findings which are irrelevant for study purposes in the Investigator's opinion)
Exclusion Criteria:
- Known or suspected allergy to lipopolysaccharide, imiquimod, or sticking plasters
- Only Part 0c: Known or suspected allergy to local anesthetics
- History of severe allergic or anaphylactic reactions to any medication • Blood donation within the last 4 weeks before the study
- Treatment with an investigational drug within three weeks before the study
- Smoking of more than 5 cigarettes per day
- Regular use of medication or abuse of alcohol
- Use of any medication within one week before the study
- Symptoms of a clinically relevant illness in the 3 months before the study
- Liver or kidney dysfunction
- Pregnancy
- History of autoimmune diseases (especially psoriasis)
- Other objections to participating in the study in the opinion of the Investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pilot Cohort for Skin Inflammation
Testing skin inflammation
|
Skin punch biopsy
LPS- or imiquimod induced skin inflammation
|
Experimental: Azithromycin and Artificial Skin Inflammation
Investigating tissue PK of Azithromycin in artificially inflamed tissue
|
LPS- or imiquimod induced skin inflammation
500 mg once daily for 3 days
|
Experimental: Azithromycin and Skin Infection
Investigating tissue PK of Azithromycin in actually infected tissue
|
500 mg once daily for 3 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 0: Area under the curve (AUC) of azithromycin in artificially inflamed tissue
Time Frame: Day 3
|
The pharmacokinetic concentration-time profile in tissue will be assessed by microdialysis.
Concentration-time profiles will be plotted.
AUC and Cmax will be used as PK parameters.
|
Day 3
|
Part 0: Maximum concentration (Cmax) of azithromycin in artificially inflamed tissue
Time Frame: Day 3
|
The pharmacokinetic concentration-time profile in tissue will be assessed by microdialysis.
Concentration-time profiles will be plotted.
AUC and Cmax will be used as PK parameters.
|
Day 3
|
Part A: Area under the curve (AUC) Azithromycin in healthy and inflamed tissue
Time Frame: Day 3
|
The pharmacokinetic concentration-time profile in tissue will be assessed by microdialysis.
Concentration-time profiles will be plotted.
AUC and Cmax will be used as PK parameters.
|
Day 3
|
Part A: Maximum concentration (Cmax) Azithromycin in healthy and inflamed tissue
Time Frame: Day 3
|
The pharmacokinetic concentration-time profile in tissue will be assessed by microdialysis.
Concentration-time profiles will be plotted.
AUC and Cmax will be used as PK parameters.
|
Day 3
|
Part B: Area under the curve (AUC) of Azithromycin in healthy and infected tissue
Time Frame: Day 3
|
The pharmacokinetic concentration-time profile in tissue will be assessed by microdialysis.
Concentration-time profiles will be plotted.
AUC and Cmax will be used as PK parameters.
|
Day 3
|
Part B: Maximum concentration (Cmax) of Azithromycin in healthy and infected tissue
Time Frame: Day 3
|
The pharmacokinetic concentration-time profile in tissue will be assessed by microdialysis.
Concentration-time profiles will be plotted.
AUC and Cmax will be used as PK parameters.
|
Day 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 0-A: Safety and tolerability of inflammation models
Time Frame: Day 0-3
|
Data will be aggregated as:
|
Day 0-3
|
Part A-B: Safety and tolerability of azithromycin
Time Frame: Day 0-3
|
Data will be presented as:
|
Day 0-3
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro_AZI_IMQ_LPS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Infection
-
Peking University People's HospitalCompletedUpper Respiratory Tract Infection | Skin Infection | Lower Respiratory Infection | Genital Infection | Subcutaneous Tissues InfectionChina
-
Mahidol UniversityDermatological Society of ThailandCompleted
-
Federico II UniversityWithdrawnInfection of Skin and/or Subcutaneous TissueItaly
-
Rothman Institute OrthopaedicsKimberly-Clark CorporationCompletedProsthetic Joint Infection | Surgical Skin InfectionUnited States
-
Zealand University HospitalNot yet recruitingFungal Infection | Inflammatory Skin Disease | Yeast Infection SkinDenmark
-
Radboud University Medical CenterCompletedBioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir (VALID-I)Varicella Zoster Virus Infection | Herpes Simplex Virus InfectionNetherlands
-
Mid and South Essex NHS Foundation TrustAnglia Ruskin UniversityNot yet recruitingScar | Suture, Complication | Symptoms and Signs | Skin Infection | Hand Infection
-
Cubist Pharmaceuticals LLCTerminatedComplicated Skin or Skin Structure InfectionUnited States
-
Medical University of ViennaCompletedDigital Technology | CLABSI - Central Line Associated Bloodstream Infection | CRBSI - Catheter Related Bloodstream InfectionAustria
-
Mayo ClinicNot yet recruitingSkin Cancer | Skin Cancer Face | Malignant Cutaneous Adnexal NeoplasmUnited States
Clinical Trials on Biopsy
-
UNICANCERNational Cancer Institute, FranceActive, not recruitingTriple-Negative Breast NeoplasmFrance
-
Postgraduate Institute of Medical Education and...CompletedLung Cancer | Endobronchial GrowthIndia
-
Chandan SenTerminatedWound Leg | Non-Diabetic Patients | Chronic Ulcer Leg/FootUnited States
-
Duke UniversityCompletedInterstitial Lung DiseaseUnited States
-
Centre Hospitalier Universitaire de NiceUnknownParodontitis Aggressive | Parodontitis ChronicFrance
-
Ardeshir RastinehadPhilips HealthcareRecruitingProstate Cancer | Prostate Disease | Elevated Prostate Specific Antigen | Family History of Prostate Cancer | Positive Digital Rectal ExamUnited States
-
Shandong Cancer Hospital and InstituteUnknownBreast Cancer | Sentinel Lymph NodeChina
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer
-
Johns Hopkins UniversityCompleted
-
Odense University HospitalNot yet recruitingProstate Cancer (Diagnosis)